Crenolanib, a TKI targeting tyrosine kinase receptors such as platelet-derived growth factor receptor A (PDGFRA), platelet-derived growth factor receptor B (PDGFRB), and FMS-like tyrosine kinase-3 (FLT3), may have clinical benefit for KRAS/BRAF-mutant CRC patients [81]. The gene discussed is BRAF; the disease is colorectal carcinoma.